ArticleFrontiers in endocrinology2025
Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Currently, anti-osteoporosis (OP) treatment imposes a certain economic burden on patients and society; therefore, studies have focused on exploring anti-OP therapies. As a classic prescription in traditional Chinese medicine (TCM), the Heidihuang Pill (HP) was clinically shown to alleviate OP. However, the mechanism behind its effect remains unclear. We aimed to determine this mechanism using methods such as network pharmacology and experimental verification. Methods: Network pharmacology was used to identify the active ingredients, targets, and mechanisms of action of HP in treating OP. Molecular docking technology was then used to verify the interactions between the active ingredients and target proteins. Finally, an OP rat model was established through Results: Overall, 178 targets were retrieved, which are key targets of HP for treating OP. Protein-Protein Interaction network analysis showed that RAC-alpha serine/threonine-protein kinase (Akt1) (degree =132) was the most reliable target of HP for treating OP. Gene Ontology functional analysis revealed that the regulation of HP on OP mainly occurs as follows: it mainly manifests as a response to hormones in biological processes; it mainly acts on membrane rafts in cellular components; and it mainly involves the binding of transcription factors in molecular functions. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis indicated that the Advanced Glycation End products/Receptor for Advanced Glycation End products (AGE-RAGE) signaling pathway in diabetic complications and the hypoxia-inducible factor (HIF)-1 signaling pathway are the main pathways involved in the HP treatment of OP. Molecular docking results showed that Akt1 has a good binding ability with peoniflorin, with a binding energy of -56.66 kcal/mol. Conclusion: Peoniflorin, the main active ingredient in HP, acts on Akt1 and treats OP through the AGE-RAGE and HIF-1 signaling pathways. This study showed the precise molecular pathways and core therapeutic targets of HP in treating OP, and provides a scientific basis and new research direction for treating OP with TCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.